Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Rote-Hand-Brief: Ixchiq (Chikungunya-Impfstoff)

Aufhebung der vorübergehenden Kontraindikation bei Erwachsenen ab 65 Jahren; Warnung vor schweren Nebenwirkungen, einschließlich Enzephalitis

Rote-Hand-Brief: Ixchiq (Chikungunya-Impfstoff) (18.09.2025)

Aktualisiert: 18.09.2025